without accounting for price concessions – namely, credit card processing fees that Regeneron paid to specialty drug distributors to benefit its customers. The DOJ further alleged that "[b]y ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at $1,100.00. Chris Schott has given his Buy rating due to a ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with ...

Democrats and other critics are now demanding that the White House disclose the list and details of the people Trump allowed to skip background ... group of individuals without any vetting beyond ...

on Thursday called for the Trump administration to provide a list of White House employees receiving a temporary Top Secret security clearance without ... for the background check process. “ ...